Recent Blog Posts

View Post: Feiba Vh (Anti-Inhibitor Coagulant Complex, Vapor Heated) Drug ...
7 Oct 2008
ANTI-INHIBITOR COAGULANT COMPLEX - INJECTION. (an-tee-in-HIB-eh-turr ko-AGG-you-lunt KOM-plex). COMMON BRAND NAME(S): Autoplex T. USES: This medication is used to treat patients with certain blood-clotting conditions (hemophilia with ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: clinical genetics: Treatment of genetic diseases: in the real ...
21 Nov 2007 by praspowt  
Anti-Inhibitor Coagulant Complex FEIBA from Baxter (can be used in both types) In mild hemophilia A or hemophiliac patients undegoing to perform oral procedure: transamin (tranexamic acid) from Daiichi. เขียนโดย praspowt ที่ 15:58 ...
View Blog: clinical genetics - http://clinicalgenetics.blogspot.com/

---

View Post: FDA Sends Letter to Baxter Over 'Clinical Thank You Email' - Drugs ...
30 Jul 2008
Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion. 1990; 30: 626-630.3Hilgartner MW, Knatterud LG, and the FEIBA Study Group. The use of factor eight inhibitor by-passing activity ...
View Blog: Drugs.com - Pharma News - http://www.drugs.com/news.html

---

View Post: Rajasthan Information Commission to review information disclosures ...
17 Jun 2006 by rtiact2005  
If these Anti Hemophilia Factor VIII, IX and Anti inhibitor coagulant complex or FEIBA( Factor VIII Inhibiting bye pass activity), are not available in the Government hospitals of Rajasthan, then what is being given to the patients of ...
View Blog: Right2Information - http://right2information.wordpress.com/

---

View Post: KOGENATE FS (Antihemophilic Factor VIII) drug information from MPR
27 Oct 2009
KOGENATE FS (Antihemophilic Factor VIII) drug information for Hemophilia A from MPR including side effects, drug interactions, dosing, contraindications and precautions. ... Anti-inhibitor Coagulant Complex (AICC) 500 units, 1000 units, 2500 units; per vial; for IV infusion after reconstitution; contains Factors II, IX, X (non-activated); Factor VII (activated); Factor VIII inhibitor bypassing activity; Prothrombin Complex Factors; heparin-free. ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: Octapharma Group and Fresenius Kabi Enter Into an Exclusive ...
27 Oct 2009 by Prne  
Frank Feller, Manager Business Development of Kabi Innovation Centre, Fresenius Kabi Deutschland GmbH, +49-6172-608-8406, frank.feller at fresenius-kabi.com; or Olaf Walter, International Business Manager, Coagulation, of Octapharma AG, ... Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies. August 25th, 2009 LACHEN, Switzerland and HOBOKEN, New Jersey - - ISTH Symposia Discuss Prevention and Eradication of FVIII Inhibitors and Introduce First ...
View Blog: PR Hub - http://blog.taragana.com/pr/

---

View Post: Critical Care
Full text
Management of bleeding following major ... ...
View Blog: Abildgaard CF, Penner JA, Watson-Williams EJ: Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980, 56:978-984. PubMed Abstract OpenURL. Menache D: Report on the task force on the

---

View Post: O-Phospho-L-Serine, Multi-functional Excipient for B Domain ...
28 Jun 2007 by Miclea RD, Purohit VS, Balu-Iyer SV  
Factor VIII (FVIII) is an important cofactor in the blood coagulation cascade. A deficiency or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding disorder. FVIII circulates in plasma as a heterodimer comprising 6 domains ... Immunogenicity of free- vs BDDrFVIII-OPLS complex was evaluated in a murine model of hemophilia A. Animals administered subcutaneous (sc) injections of BDDrFVIII-OPLS had lower neutralizing titers compared with animals treated with ...
View Blog: The AAPS Journal - http://www.aapsj.org/

---

View Post: Ipsen In 3 Deals Worth $450M; Company to Build A Fully-Fledged ...
5 Jun 2008
Congenital hemophilia A is a genetic bleeding disorder resulting in a deficiency of coagulation FVIII. This disease affects male predominantly with an incidence of 1 in 5000 male birth. According to the Centers for Disease Control there are ... Since porcine FVIII (pFVIII) possesses low cross reactivity to anti-hFVIII antibodies, it is expected that OBI-1 can be used to stop bleeding in hemophilia patients with inhibitor using the same natural pathway as human Factor VIII ...
View Blog: BioSpace.com Featured News and Stories - http://www.biospace.com/

---

View Post: Use of recombinant factor VIIa for emergency reversal of ...
3 May 2007
More rapid reversal of anticoagulation may be achieved by infusion of either fresh-frozen plasma (FFP) or prothrombin complex concentrates (PCCs). However, these agents are inconsistent in their action on INR or PTT, require a long ..... Kenet G. High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors. Semin Hematol 2006;43:S108-10. Back to cited text no. 21. 22. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service ...
View Blog: Table of Contents : Journal of Postgraduate... - http://www.jpgmonline.com/currentissue.asp

---